These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 31926324)

  • 1. Novel scoring system for recurrence risk classification of surgically resected G1/2 pancreatic neuroendocrine tumors - Retrospective cohort study.
    Zou S; Jiang Y; Wang W; Zhan Q; Deng X; Shen B
    Int J Surg; 2020 Feb; 74():86-91. PubMed ID: 31926324
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of risk factors for recurrence after curative resection of well-differentiated pancreatic neuroendocrine tumors based on the new grading classification.
    Tsutsumi K; Ohtsuka T; Fujino M; Nakashima H; Aishima S; Ueda J; Takahata S; Nakamura M; Oda Y; Tanaka M
    J Hepatobiliary Pancreat Sci; 2014 Jun; 21(6):418-25. PubMed ID: 24142395
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel recurrence risk stratification of resected pancreatic neuroendocrine tumor.
    Gao H; Liu L; Wang W; Xu H; Jin K; Wu C; Qi Z; Zhang S; Liu C; Xu J; Ni Q; Yu X
    Cancer Lett; 2018 Jan; 412():188-193. PubMed ID: 29107104
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictive value of preoperative peripheral blood neutrophil/lymphocyte ratio for lymph node metastasis in patients of resectable pancreatic neuroendocrine tumors: a nomogram-based study.
    Tong Z; Liu L; Zheng Y; Jiang W; Zhao P; Fang W; Wang W
    World J Surg Oncol; 2017 May; 15(1):108. PubMed ID: 28558772
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relapse-free survival in patients with nonmetastatic, surgically resected pancreatic neuroendocrine tumors: an analysis of the AJCC and ENETS staging classifications.
    Strosberg JR; Cheema A; Weber JM; Ghayouri M; Han G; Hodul PJ; Kvols LK
    Ann Surg; 2012 Aug; 256(2):321-5. PubMed ID: 22415420
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Prognostic Scoring System for the Prediction of Metastatic Recurrence Following Curative Resection of Pancreatic Neuroendocrine Tumors.
    Sho S; Court CM; Winograd P; Toste PA; Pisegna JR; Lewis M; Donahue TR; Hines OJ; Reber HA; Dawson DW; Tomlinson JS
    J Gastrointest Surg; 2019 Jul; 23(7):1392-1400. PubMed ID: 30353489
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recurrence of Pancreatic Neuroendocrine Tumors and Survival Predicted by Ki67.
    Genç CG; Falconi M; Partelli S; Muffatti F; van Eeden S; Doglioni C; Klümpen HJ; van Eijck CHJ; Nieveen van Dijkum EJM
    Ann Surg Oncol; 2018 Aug; 25(8):2467-2474. PubMed ID: 29789972
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic factors and survival after surgical resection of pancreatic neuroendocrine tumor with validation of established and modified staging systems.
    Benetatos N; Hodson J; Marudanayagam R; Sutcliffe RP; Isaac JR; Ayuk J; Shah T; Roberts KJ
    Hepatobiliary Pancreat Dis Int; 2018 Apr; 17(2):169-175. PubMed ID: 29576279
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical outcome and long-term survival of 150 consecutive patients with pancreatic neuroendocrine tumors: A comprehensive analysis by the World Health Organization 2010 grading classification.
    Deng BY; Liu F; Yin SN; Chen AP; Xu L; Li B
    Clin Res Hepatol Gastroenterol; 2018 Jun; 42(3):261-268. PubMed ID: 29307515
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A single institution's 26-year experience with nonfunctional pancreatic neuroendocrine tumors: a validation of current staging systems and a new prognostic nomogram.
    Ellison TA; Wolfgang CL; Shi C; Cameron JL; Murakami P; Mun LJ; Singhi AD; Cornish TC; Olino K; Meriden Z; Choti M; Diaz LA; Pawlik TM; Schulick RD; Hruban RH; Edil BH
    Ann Surg; 2014 Feb; 259(2):204-12. PubMed ID: 23673766
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of Outcomes Following Surgery for Locally Advanced Pancreatic Neuroendocrine Tumors.
    Titan AL; Norton JA; Fisher AT; Foster DS; Harris EJ; Worhunsky DJ; Worth PJ; Dua MM; Visser BC; Poultsides GA; Longaker MT; Jensen RT
    JAMA Netw Open; 2020 Nov; 3(11):e2024318. PubMed ID: 33146734
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic value of CT-based radiomics in grade 1-2 pancreatic neuroendocrine tumors.
    Heo S; Park HJ; Kim HJ; Kim JH; Park SY; Kim KW; Kim SY; Choi SH; Byun JH; Kim SC; Hwang HS; Hong SM
    Cancer Imaging; 2024 Feb; 24(1):28. PubMed ID: 38395973
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Survival Analyses for Patients With Surgically Resected Pancreatic Neuroendocrine Tumors by World Health Organization 2010 Grading Classifications and American Joint Committee on Cancer 2010 Staging Systems.
    Yang M; Ke NW; Zhang Y; Zeng L; Tan CL; Zhang H; Mai G; Tian BL; Liu XB
    Medicine (Baltimore); 2015 Dec; 94(48):e2156. PubMed ID: 26632896
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic factors in 151 patients with surgically resected non-functioning pancreatic neuroendocrine tumours.
    Song KB; Kim SC; Kim JH; Hong SM; Park KM; Hwang DW; Lee JH; Lee YJ
    ANZ J Surg; 2016 Jul; 86(7-8):563-7. PubMed ID: 25040037
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pancreatic neuroendocrine tumors: Preoperative factors that predict lymph node metastases to guide operative strategy.
    Postlewait LM; Ethun CG; Baptiste GG; Le N; McInnis MR; Cardona K; Russell MC; Sarmiento JM; Kooby DA; Staley CA; Maithel SK
    J Surg Oncol; 2016 Sep; 114(4):440-5. PubMed ID: 27334541
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multi-institutional Development and External Validation of a Nomogram to Predict Recurrence After Curative Resection of Pancreatic Neuroendocrine Tumors.
    Pulvirenti A; Javed AA; Landoni L; Jamieson NB; Chou JF; Miotto M; He J; Gonen M; Pea A; Tang LH; Nessi C; Cingarlini S; D'Angelica MI; Gill AJ; Kingham TP; Scarpa A; Weiss MJ; Balachandran VP; Samra JS; Cameron JL; Jarnagin WR; Salvia R; Wolfgang CL; Allen PJ; Bassiy C
    Ann Surg; 2021 Dec; 274(6):1051-1057. PubMed ID: 31567347
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Novel Validated Recurrence Risk Score to Guide a Pragmatic Surveillance Strategy After Resection of Pancreatic Neuroendocrine Tumors: An International Study of 1006 Patients.
    Zaidi MY; Lopez-Aguiar AG; Switchenko JM; Lipscomb J; Andreasi V; Partelli S; Gamboa AC; Lee RM; Poultsides GA; Dillhoff M; Rocha FG; Idrees K; Cho CS; Weber SM; Fields RC; Staley CA; Falconi M; Maithel SK
    Ann Surg; 2019 Sep; 270(3):422-433. PubMed ID: 31283562
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neuroendocrine tumors of the pancreas: Degree of cystic component predicts prognosis.
    Cloyd JM; Kopecky KE; Norton JA; Kunz PL; Fisher GA; Visser BC; Dua MM; Park WG; Poultsides GA
    Surgery; 2016 Sep; 160(3):708-13. PubMed ID: 27216830
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictive Value of Chromogranin A and a Pre-Operative Risk Score to Predict Recurrence After Resection of Pancreatic Neuroendocrine Tumors.
    Fisher AV; Lopez-Aguiar AG; Rendell VR; Pokrzywa C; Rocha FG; Kanji ZS; Poultsides GA; Makris EA; Dillhoff ME; Beal EW; Fields RC; Panni RZ; Idrees K; Smith PM; Cho CS; Beems MV; Maithel SK; Winslow ER; Abbott DE; Weber SM
    J Gastrointest Surg; 2019 Apr; 23(4):651-658. PubMed ID: 30659439
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pancreatic neuroendocrine tumor: A multivariate analysis of factors influencing survival.
    Birnbaum DJ; Turrini O; Ewald J; Barbier L; Autret A; Hardwigsen J; Brunet C; Moutardier V; Le Treut YP; Delpero JR
    Eur J Surg Oncol; 2014 Nov; 40(11):1564-71. PubMed ID: 25086992
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.